This paper describes the existing European Union legislation and scientific guidance to adequately assess the quality, safety and efficacy, as well as the lifecycle management, of the group of non-biological complex drug (NBCD) products, including nanomedicines such as liposomes, polymeric micelles, glatiramoids and iron-carbohydrate complexes.
No takes yet. Share an insight, caveat, or question.
Ehmann et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: